SAN DIEGO, April 12, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of
Ron Squarer to the Company’s Board of Directors, effective immediately. Mr. Squarer is chief executive officer and a director of
Array BioPharma Inc., a biopharmaceutical company focused on the discovery, development, and commercialization of targeted small
molecule therapies.
“With more than two decades of commercial, operational, and development achievements in the biopharma sector,
Ron’s insight will be a valuable resource as we execute on our strategic initiatives in the years ahead. We look forward to his
leadership,” said Stephen Aselage, chief executive officer of Retrophin.
Mr. Squarer has served as Array’s CEO and member of the Board of Directors since 2012. Previously, Mr. Squarer
was chief commercial officer at Hospira, Inc., in which role he was responsible for delivering $4 billion in annual revenue. This
was preceded by his tenure at Hospira as senior vice president, Global Marketing and Corporate Development. Prior to this, Mr.
Squarer held senior management positions at Mayne Pharma (acquired by Hospira), Pfizer, Inc., and SmithKline Beecham
Pharmaceuticals (now GlaxoSmithKline). Mr. Squarer earned his bachelor’s degree from the University of California, Berkeley and
master’s degree in business administration from the Kellogg School of Management, Northwestern University.
Additionally, upon the conclusion of his current term as director, Cornelius “Neal” Golding will be stepping
down from the Board at the Company’s 2017 Annual Meeting of Stockholders. “Neal’s leadership has been influential in our evolution
and we are grateful for his significant contributions and outstanding service on the board,” said Mr. Aselage.
About Retrophin
Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to
people living with rare diseases who have few, if any, treatment options. The Company's approach centers on its pipeline featuring
late-stage candidates targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental
glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease,
and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically
begins in early childhood. Research exploring the potential of early-stage assets in several rare diseases is also underway.
Retrophin's R&D efforts are supported by revenues from the Company's commercial products, Thiola®, Cholbam®, and Chenodal®.
Retrophin.com
Forward-Looking Statements
This press release contains "forward-looking statements" as that term is defined in the Private Securities
Litigation Reform Act of 1995, regarding the research, development and commercialization of pharmaceutical products. Without
limiting the foregoing, these statements are often identified by the words "may", "might", "believes", "thinks", "anticipates",
"plans", "expects", "intends" or similar expressions. In addition, expressions of our strategies, intentions or plans are also
forward-looking statements. Such forward-looking statements are based on current expectations and involve inherent risks and
uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to
differ materially from current expectations. No forward-looking statement can be guaranteed. Among the factors that could cause
actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated
with the Company's business and finances in general, success of its commercial products as well as risks and uncertainties
associated with the Company's pre-clinical and clinical stage pipeline. You are cautioned not to place undue reliance on these
forward-looking statements as there are important factors that could cause actual results to differ materially from those in
forward-looking statements, many of which are beyond our control. The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information, future events, or otherwise. Investors are referred to the full
discussion of risks and uncertainties as included in the Company's most recent 10-K and other filings with the Securities and
Exchange Commission.
Contact: Chris Cline, CFA Vice President, Investor Relations 646-564-3680 IR@retrophin.com
